Cargando…

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension

OBJECTIVE: We compared the haemodynamic effects of riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent/recurrent CTEPH after pulmonary endarterectomy in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Nick H, D'Armini, Andrea M, Grimminger, Friedrich, Grünig, Ekkehard, Hoeper, Marius M, Jansa, Pavel, Mayer, Eckhard, Neurohr, Claus, Simonneau, Gérald, Torbicki, Adam, Wang, Chen, Fritsch, Arno, Davie, Neil, Ghofrani, Hossein-Ardeschir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Pulmonary Vascular Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529957/ https://www.ncbi.nlm.nih.gov/pubmed/28011757 http://dx.doi.org/10.1136/heartjnl-2016-309621

Ejemplares similares

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015)

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
por: McLaughlin, Vallerie V., et al.
Publicado: (2017)

Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: the UK experience
por: Hoole, Stephen P, et al.
Publicado: (2020)

Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension
por: Wiedenroth, Christoph B., et al.
Publicado: (2018)

Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH
por: Gall, Henning, et al.
Publicado: (2018)

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
por: Hoeper, Marius M., et al.
Publicado: (2017)

Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2020)

Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
por: Ghofrani, Hossein A, et al.
Publicado: (2009)

Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study
por: Simonneau, Gérald, et al.
Publicado: (2020)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
por: Marra, Alberto M., et al.
Publicado: (2018)

Prevalence and haemodynamic profiles of pulmonary hypertension in cardiac amyloidosis
por: Slivnick, Jeremy, et al.
Publicado: (2022)

Effects of riociguat in severe experimental pulmonary hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2011)

Prognostic value of TAPSE after therapy optimisation in patients with pulmonary arterial hypertension is independent of the haemodynamic effects of therapy
por: Ghio, Stefano, et al.
Publicado: (2016)

Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular–Pulmonary Arterial Coupling
por: Taran, Irina N., et al.
Publicado: (2018)

Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
por: Benza, Raymond L., et al.
Publicado: (2020)

Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies
por: Thenappan, Thenappan, et al.
Publicado: (2020)

SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2017)

Efficacy of cardiac rehabilitation after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
por: Fukui, Shigefumi, et al.
Publicado: (2016)

CASE REPORT OF A COVID-19 INFECTION AND THROMBOEMBOLISM IN A PATIENT WITH ULCERATIVE COLITIS ON TOFACITINIB
por: SOMPALLI, SREEJA, et al.
Publicado: (2021)

Diagnostic advances and opportunities in chronic thromboembolic pulmonary hypertension
por: D'Armini, Andrea M.
Publicado: (2015)

Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial( )
por: Dachs, Theresa Marie, et al.
Publicado: (2022)

The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats
por: Lang, Michaela, et al.
Publicado: (2011)

Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies
por: Cartin-Ceba, Rodrigo, et al.
Publicado: (2018)

Quality of life in patients with chronic thromboembolic pulmonary hypertension
por: Mathai, Stephen C., et al.
Publicado: (2016)

Characteristics and in-hospital outcomes of patients undergoing balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a time-trend analysis from the Japanese nationwide registry
por: Minatsuki, Shun, et al.
Publicado: (2021)

Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension
por: Jenkins, David, et al.
Publicado: (2017)

Pulmonary Thrombosis and Thromboembolism in COVID-19
por: Poor, Hooman D.
Publicado: (2021)

Medical management of chronic thromboembolic pulmonary hypertension
por: Pepke-Zaba, Joanna, et al.
Publicado: (2017)

Evaluation and Management of Chronic Thromboembolic Pulmonary Hypertension
por: Yang, Jenny, et al.
Publicado: (2023)

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Benza, Raymond L., et al.
Publicado: (2022)

Practical management of riociguat in patients with pulmonary arterial hypertension
por: Halank, Michael, et al.
Publicado: (2019)

Surgical specimens, haemodynamics and long-term outcomes after pulmonary endarterectomy
por: Skoro-Sajer, Nika, et al.
Publicado: (2014)

Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: a randomised clinical study
por: Gerhardt, Felix, et al.
Publicado: (2017)

The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats
por: Lang, Michaela, et al.
Publicado: (2012)

Riociguat for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): A subgroup analysis from the PATENT studies
por: Stephan, Rosenkranz, et al.
Publicado: (2015)

Exercise Training Improves Exercise Capacity and Quality of Life in Patients with Inoperable or Residual Chronic Thromboembolic Pulmonary Hypertension
por: Nagel, Christian, et al.
Publicado: (2012)

Balloon pulmonary angioplasty vs riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension: A systematic review and meta‐analysis
por: Wang, Wuwan, et al.
Publicado: (2019)

Results From the United States Chronic Thromboembolic Pulmonary Hypertension Registry: Enrollment Characteristics and 1-Year Follow-up
por: Kerr, Kim M., et al.
Publicado: (2021)

Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Harzheim, Dominik, et al.
Publicado: (2013)

Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial
por: Souza, Rogerio, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_47dfrjhcdcrfh3p5n02tghe6tn